Skip to content
PubMed This is a summary of 46 peer-reviewed journal articles Updated
Pediatric Neurology

Juvenile Onset Parkinson Disease 19A (PARK19A): A Patient Guide

At a Glance

PARK19A is a rare inherited condition caused by changes in both copies of the DNAJC6 gene. Children may have developmental or movement problems, seizures, or swallowing difficulty, and care is tailored by a team of specialists and therapists.

Juvenile onset Parkinson disease 19A (PARK19A) is an exceptionally rare genetic condition that fundamentally changes how the brain’s nerve cells communicate. It is an autosomal recessive disorder caused by mutations in the DNAJC6 gene, which means a child must inherit a changed copy of the gene from both parents to develop the condition [1]. This gene is responsible for producing a protein called auxilin, which acts as a specialized “recycling” tool in the brain. Without working auxilin, the brain’s “messenger bubbles” (synaptic vesicles) cannot be efficiently reused, leading to a breakdown in the signals that control movement and development [2].

While the condition is named for its similarity to Parkinson’s disease, PARK19A is a spectrum and can present as a complex multisystem disorder that involves more than just tremors or stiffness. In the reported severe juvenile form, the condition often begins in early childhood with developmental delays or the loss of previously gained skills, a process known as neurological regression [3]. In addition to movement challenges like bradykinesia (slowness) and dystonia (involuntary muscle twisting), children may experience seizures, difficulties with swallowing (dysphagia), and changes in their ability to learn and interact with the world [4]. It is important to know this describes reported features of the complex juvenile phenotype, not an inevitable course for every child, particularly those with the more slowly progressive early-onset parkinsonism phenotype.

A definitive molecular diagnosis generally requires a compatible clinical picture alongside genetic testing—such as comprehensive gene panels, Whole Exome Sequencing (WES), or other methods—to identify pathogenic or likely pathogenic variants in both copies of the DNAJC6 gene. Once a diagnosis is confirmed, care shifts toward a highly personalized approach. Because no two children respond to medications exactly the same way—and some can be quite sensitive to standard treatments like levodopa—management requires a multidisciplinary care team [5]. This team, led by a pediatric movement disorders specialist and supported by speech, physical, and occupational therapists, works together to protect your child’s safety and improve their daily function.

Living with a PARK19A diagnosis is a journey through uncharted territory, but you are not alone in navigating it. While the rarity of the condition brings uncertainty, it also means that every observation you make as a parent is vital to your child’s care plan. By focusing on symptom management, nutritional support, and safety monitoring, you can help your child maintain the best possible quality of life while researchers continue to work toward a deeper understanding of this complex condition [6].

Common questions in this guide

What is PARK19A, and how is it inherited?
PARK19A is a rare inherited neurological condition linked to changes in the DNAJC6 gene, which helps brain cells recycle the tiny structures used to send signals. It follows an autosomal recessive pattern, so a child generally needs a changed copy of the gene from both parents.
What symptoms can a child with PARK19A have?
Reported features of the severe juvenile form include developmental delay or loss of previously learned skills, slow movement, involuntary muscle twisting, seizures, and trouble swallowing. PARK19A is a spectrum condition, so the severity and pace of progression can differ, and not every child has all of these features.
How is juvenile-onset PARK19A diagnosed?
Diagnosis usually combines clinical features with genetic testing, such as a comprehensive gene panel or whole exome sequencing. The testing looks for pathogenic or likely pathogenic variants in both copies of DNAJC6.
What kind of care does a child with PARK19A need?
Care is individualized and may involve a pediatric movement-disorders specialist, speech therapist, physical therapist, and occupational therapist. The team focuses on movement and daily function, nutrition, swallowing, seizure monitoring, and safety, while medication choices are monitored closely.
Can levodopa be used for PARK19A?
Levodopa is one standard movement treatment that may be considered, but children with PARK19A can respond differently and some may be sensitive to it. A pediatric movement-disorders specialist should guide whether it is appropriate and monitor the response.
How can families prepare for PARK19A-related safety concerns?
Families can work with the care team to identify immediate priorities, which may include movement support, seizure monitoring, swallowing evaluation, nutrition, and fall or injury prevention. Caregivers’ observations about daily changes can help the team adjust the care plan.

Get notified when new evidence is published on Juvenile onset Parkinson disease 19A.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (6)
  1. 1

    DNAJC6 Mutations Disrupt Dopamine Homeostasis in Juvenile Parkinsonism-Dystonia.

    Ng J, Cortès-Saladelafont E, Abela L, et al.

    Movement disorders : official journal of the Movement Disorder Society 2020; (35(8)):1357-1368 doi:10.1002/mds.28063.

    PMID: 32472658
  2. 2

    The Role of Co-chaperones in Synaptic Proteostasis and Neurodegenerative Disease.

    Gorenberg EL, Chandra SS

    Frontiers in neuroscience 2017; (11()):248 doi:10.3389/fnins.2017.00248.

    PMID: 28579939
  3. 3

    Novel Homozygous Pathogenic Variant in DNAJC6 Causes Rapid Progressive Parkinsonism.

    Pessoa ALS, Guimarães TG, de Castro Dos Santos D, et al.

    Movement disorders clinical practice 2026; doi:10.1002/mdc3.70731.

    PMID: 42414182
  4. 4

    Childhood-onset parkinsonism, dystonia and severe muscle wasting in a Sudanese girl caused by a novel homozygous DnaJ heat shock protein family (heat shock protein 40) member C6 frameshift variant, with an incidental pathogenic breast cancer 1 gene secondary finding: a case report.

    Ahmed KAHM, Ahmed RKY

    Journal of medical case reports 2026; (20(1)).

    PMID: 42897672
  5. 5

    Crossing barriers: a multidisciplinary approach to children and adults with young-onset movement disorders.

    van Egmond ME, Eggink H, Kuiper A, et al.

    Journal of clinical movement disorders 2018; (5()):3 doi:10.1186/s40734-018-0070-x.

    PMID: 29636982
  6. 6

    Pediatric parkinsonism: clinical review and a proposed clinical algorithm.

    Naranjo-Lobo V, Hidalgo-Bravo MJ, Munoz-Chesta D, Troncoso-Schifferli M

    Frontiers in neurology 2026; (17()):1788936 doi:10.3389/fneur.2026.1788936.

    PMID: 42483444

This page is for informational purposes only and does not constitute medical advice about your child’s PARK19A diagnosis. Your child’s pediatric movement-disorders specialist and multidisciplinary care team should interpret genetic results and guide treatment, swallowing, seizure, and safety decisions.